The mechanisms of action of nicotinamide and zinc in inflammatory skin disease

Cutis

Volumn 77, Issue 1 SUPPL., 2006, Pages 5-10

  Fivenson, David R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; NICOMIDE; NICOTINAMIDE; ZINC;

ACNE VULGARIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; HUMAN; IMMUNOLOGY; LIPOGENESIS; METABOLISM; MICROBIOLOGY; PATHOLOGY; PROPIONIBACTERIUM ACNES; REVIEW; SEBACEOUS GLAND;

ACNE VULGARIS; ANTI-INFLAMMATORY AGENTS; DRUG COMBINATIONS; HUMANS; LIPOGENESIS; MOLECULAR STRUCTURE; NIACINAMIDE; PROPIONIBACTERIUM ACNES; SEBACEOUS GLANDS; ZINC;

EID: 31944448573     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Hendler SS, Rorvik D. PDR for Nutritional Supplements. 1st ed. Montvale, NJ: Medical Economics Co; 2001.
2. Stratford MR, Rojas A, Hall DW, et al. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol. 1992;25:37-42.
3. Griffiths CEM. Nicotinamide 4% gel for the treatment of inflammatory acne vulgaris. J Dermatol Treat. 1995;6(suppl 1):S8-S10.
4. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753-758.
5. Dreno B, Amblard P, Agache P, et al. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol. 1989;69:541-543.
6. Dreno B, Trossaert M, Boiteau HL, et al. Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol. 1992;72:250-252.
7. Rebello T, Atherton DJ, Holden C. The effect of oral zinc administration on sebum free fatty acids in acne vulgaris. Acta Derm Venereol. 1986;66:305-310.
8. Dreno B, Foulc P, Reynaud A, et al. Effect of zinc gluconate on Propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol. 2005;15:152-155.
9. Nicomide (nicotinamide, zinc, copper, and folic acid) tablets [package insert]. Vernon Hills, Ill: Sirius Laboratories, Inc; 2003.
10. Thepen T, Langeveld-Wildschut EG, Bihari IC, et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol. 1996;97:828-837.
11. Grewe M, Walther S, Gyufko K, et al. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol. 1995;105:407-410.
12. Hanifin JM, Chan S. Biochemical and immunologie mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol. 1999;41:72-77.
13. Webster GF. Inflammatory acne represents hypersensitivity to Propionibacterium acnes. Dermatology. 1998;196:80-81.
14. Dicarlo JB, McCall CO. Pharmacologic alternatives for severe atopic dermatitis. Int J Dermatol. 2001;40:82-88.
15. Shimoyama M, Kawai M, Hoshi Y, et al. Nicotinamide inhibition of 3′,5′-cyclic AMP phosphodiesterase in vitro. Biochem Biophys Res Commun. 1972;49:1137-1141.
16. Wyczolkowska J, Maslinski C. Inhibition by nicotinamide of an homologous PCA reaction and antigen-induced histamine release from rat peritoneal mast cells. Int Arch Allergy Appl Immunol. 1975;49:285-292.
17. Bekier E, Wyczolkowska J, Szyc H, et al. The inhibitory effect of nicotinamide on asthma-like symptoms and eosinophilia in guinea pigs, anaphylactic mast cell degranulation in mice, and histamine release from rat isolated peritoneal mast cells by compound 48-80. Int Arch Allergy Appl Immunol 1974;47:737-748.
18. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. a preliminary report. Arch Dermatol. 1986;122:670-674.
19. Matts PJ, Oblong JE, Bissett DL. A review of the range of effects of niacinamide in human skin. IFSCC Magazine. 2002;5:285-289.
20. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169:1535-1541.
21. Shalita AR, Smith JG, Parish LC, et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34: 434-437.
22. Bekier E, Maslinski C. Antihistaminic action of nicotinamide. Agents Actions. 1974;4:196.
23. Kohler IK, Lorincz AL. Erythema elevatum diutinum treated with niacinamide and tetracycline. Arch Dermatol. 1980;116:693-695.
24. Ma A, Medenica M. Response of generalized granuloma annulare to high-dose niacinamide. Arch Dermatol. 1983;119:836-839.
25. Burger DR, Vandenbark AA, Daves D, et al. Nicotinamide: suppression of lymphocyte transformation with a component identified in human transfer factor. J Immunol. 1976;117:797-801.
26. Namazi MR. Nicotinamide: a potential addition to the anti-psoriatic weaponry. FASEB J. 2003;17:1377-1379.
27. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54: 375-429.
28. Kirkland JB. Niacin and carcinogenesis. Nutr Cancer. 2003;46:110-118.
29. Duschet P, Schwarz T, Gschnait F. Bullous pemphigoid after radiation therapy. J Am Acad Dermatol. 1988;18:441-444.
30. Chen S, Lu X, Zhou G. Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline. Int Dermatol. 2003;42:981-982.
31. Shah SA, Ormerod AD. Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide. Clin Exp Dermatol. 2000;25:204-205.
32. Baba T, Sonozaki H, Seki K, et al. An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Imnumol. 1976;116:112-116.
33. Mogavero HSJ, Meirer MG, Newball MM, et al. Enzymatic activity in bullous pemphigoid blister fluids [abstract]. Clin Res. 1982;30:598A.
34. Biedermann KA, Lammers K, Mrowczynski E, et al. Regulation of sebum production by niacinamide. Poster presented at: 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, La. P81.
35. Majeski JA, Alexander JW. Evaluation of tetracycline in the neutrophil chemotactic response. J Lab Clin Med. 1977;90:259-265.
36. Esterly NB, Koransky JS, Furey NL, et al. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch Dermatol. 1984;120:1308-1313.
37. Humbert P, Renaud A, Millet J, et al. Evaluation of the effect of heparin and tetracycline on the cohesion of the dermal-epidermal junction. Acta Derm Venereol. 1989;69:434-436.
38. Bernstein JE, Lorincz AL. The effects of topical nicotinamide, tetracycline, and dapsone on potassium iodide-induced inflammation. J Invest Dermatol. 1980;74:257-258.
39. Ludwig A, Dietel M, Schafer G, et al. Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin. Cancer Res. 1990;50:2470-2475.
40. Wilson GL, Patton NJ, McCord JM, et al. Mechanisms of streptozotocin- and alloxan-induced damage in rat B cells. Diabetologia. 1984;27:587-591.
41. Hayward AR, Herberger M. Nicotinamide protects target cells from cell-mediated cytolysis. Cell Immunol. 1988;113:414-422.
42. Hoffer A. LSD-induced psychosis and vitamin B 3. Am J Psychiatry. 1972;128:1155.
43. Scherer B, Kramer W. Influence of niacinamide administration on brain 5-HT and a possible mode of action. Life Sci I. 1972;11:189-195.
44. Hoffer A. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. Schizophrenia. 1969;1:78-87.
45. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43:1337-1345.
46. Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med. 1973;289:1180-1182.
47. McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271: 672-677.
48. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000;86(12A):35L-40L.
49. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28:998-1000.
50. Kawahara Y, Hashimoto T, Watanabe K, et al. Two cases of atypical bullous disease showing linear IgG and IgA deposition in the basement membrane zone. J Dermatol. 1996;23:254-258.
51. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol. 1997;36:101-103.
52. Poskitt L, Wojnarowska F. Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol. 1995;20:258-259.
53. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol. 1998;23:254-257.
54. Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol. 1986;115:77-80.
55. Fivenson DP, Kimbrough TL. Lichen planus pemphigoides: combination therapy with tetracycline and nicotinamide. J Am Acad Dermatol. 1997;36:638-640.